Literature DB >> 29700232

3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine.

Yunden Jinsmaa1, Yehonatan Sharabi2, Patti Sullivan2, Risa Isonaka2, David S Goldstein2.   

Abstract

The catecholaldehyde hypothesis posits that 3,4-dihydroxyphenylacetaldehyde (DOPAL), an obligate intermediary metabolite of dopamine, is an autotoxin that challenges neuronal homeostasis in catecholaminergic neurons. DOPAL toxicity may involve protein modifications, such as oligomerization of α-synuclein (AS). Potential interactions between DOPAL and other proteins related to catecholaminergic neurodegeneration, however, have not been systemically explored. This study examined DOPAL-induced protein-quinone adduct formation ("quinonization") and protein oligomerization, ubiquitination, and aggregation in cultured MO3.13 human oligodendrocytes and PC12 rat pheochromocytoma cells and in test tube experiments. Using near-infrared fluorescence spectroscopy, we detected spontaneous DOPAL oxidation to DOPAL-quinone, DOPAL-induced quinonization of intracellular proteins in both cell lines, and DOPAL-induced quinonization of several proteins related to catecholaminergic neurodegeneration, including AS, the type 2 vesicular monoamine transporter, glucocerebrosidase, ubiquitin, and l-aromatic-amino-acid decarboxylase (LAAAD). DOPAL also oligomerized AS, ubiquitin, and LAAAD; inactivated LAAAD (IC50 54 μM); evoked substantial intracellular protein ubiquitination; and aggregated intracellular AS. Remarkably, N-acetylcysteine, which decreases DOPAL-quinone formation, attenuated or prevented all of these protein modifications and functional changes. The results fit with the proposal that treatments based on decreasing the formation and oxidation of DOPAL may slow or prevent catecholaminergic neurodegeneration. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29700232      PMCID: PMC5988001          DOI: 10.1124/jpet.118.248492

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  55 in total

Review 1.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

2.  A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease.

Authors:  David S Goldstein; Patricia Sullivan; Courtney Holmes; Gary W Miller; Yehonatan Sharabi; Irwin J Kopin
Journal:  J Neurochem       Date:  2014-06-13       Impact factor: 5.372

3.  Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders.

Authors:  Ozlem Goker-Alpan; Barbara K Stubblefield; Benoit I Giasson; Ellen Sidransky
Journal:  Acta Neuropathol       Date:  2010-09-14       Impact factor: 17.088

4.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

5.  Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).

Authors:  Cristian Follmer; Eduardo Coelho-Cerqueira; Danilo Y Yatabe-Franco; Gabriel D T Araujo; Anderson S Pinheiro; Gilberto B Domont; David Eliezer
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

6.  Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.

Authors:  Jennifer N Rees; Virginia R Florang; Laurie L Eckert; Jonathan A Doorn
Journal:  Chem Res Toxicol       Date:  2009-07       Impact factor: 3.739

7.  Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite.

Authors:  David G Anderson; Virginia R Florang; Josephine H Schamp; Garry R Buettner; Jonathan A Doorn
Journal:  Chem Res Toxicol       Date:  2016-06-15       Impact factor: 3.739

8.  The small heat shock protein Hsp27 binds α-synuclein fibrils, preventing elongation and cytotoxicity.

Authors:  Dezerae Cox; Daniel R Whiten; James W P Brown; Mathew H Horrocks; Rebecca San Gil; Christopher M Dobson; David Klenerman; Antoine M van Oijen; Heath Ecroyd
Journal:  J Biol Chem       Date:  2018-01-30       Impact factor: 5.157

9.  Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity.

Authors:  Mustafa T Ardah; Katerina E Paleologou; Guohua Lv; Salema B Abul Khair; Abdulla S Kazim; Saeed T Minhas; Taleb H Al-Tel; Abdulmonem A Al-Hayani; Mohammed E Haque; David Eliezer; Omar M A El-Agnaf
Journal:  Front Aging Neurosci       Date:  2014-08-05       Impact factor: 5.750

10.  DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.

Authors:  N Plotegher; G Berti; E Ferrari; I Tessari; M Zanetti; L Lunelli; E Greggio; M Bisaglia; M Veronesi; S Girotto; M Dalla Serra; C Perego; L Casella; L Bubacco
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

View more
  16 in total

Review 1.  How does homeostasis happen? Integrative physiological, systems biological, and evolutionary perspectives.

Authors:  David S Goldstein
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-01-16       Impact factor: 3.619

2.  3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing α-Synuclein.

Authors:  Yunden Jinsmaa; Risa Isonaka; Yehonatan Sharabi; David S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2019-11-19       Impact factor: 4.030

Review 3.  The catecholaldehyde hypothesis: where MAO fits in.

Authors:  David S Goldstein
Journal:  J Neural Transm (Vienna)       Date:  2019-12-05       Impact factor: 3.575

4.  Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases.

Authors:  David S Goldstein; Mark J Pekker; Graeme Eisenhofer; Yehonatan Sharabi
Journal:  JCI Insight       Date:  2019-07-23

5.  Modeling the Progression of Cardiac Catecholamine Deficiency in Lewy Body Diseases.

Authors:  David S Goldstein; Mark J Pekker; Patti Sullivan; Risa Isonaka; Yehonatan Sharabi
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

6.  Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction.

Authors:  Chung-Yang Kao; Mafei Xu; Leiming Wang; Shih-Chieh Lin; Hui-Ju Lee; Lita Duraine; Hugo J Bellen; David S Goldstein; Sophia Y Tsai; Ming-Jer Tsai
Journal:  PLoS Genet       Date:  2020-06-24       Impact factor: 5.917

Review 7.  Impaired dopamine metabolism in Parkinson's disease pathogenesis.

Authors:  Anna Masato; Nicoletta Plotegher; Daniela Boassa; Luigi Bubacco
Journal:  Mol Neurodegener       Date:  2019-08-20       Impact factor: 14.195

Review 8.  Are Proteinopathy and Oxidative Stress Two Sides of the Same Coin?

Authors:  Nihar J Mehta; Praneet Kaur Marwah; David Njus
Journal:  Cells       Date:  2019-01-16       Impact factor: 6.600

Review 9.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

10.  Stable expression of the human dopamine transporter in N27 cells as an in vitro model for dopamine cell trafficking and metabolism.

Authors:  B S Cagle; M L Sturgeon; J B O'Brien; J C Wilkinson; R A Cornell; D L Roman; J A Doorn
Journal:  Toxicol In Vitro       Date:  2021-07-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.